Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Nezavist in Healthy Adults
NCT06633562Phase 1Terminated
- Sponsor
- Lohocla Research Corporation
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Nezavist SDD in alcohol use disorder (AUD) (5 arms), sponsored by Lohocla Research Corporation. Primary endpoints: Safety and Tolerability (Adverse Events) up to 7 days and Maximum Tolerated Dose up to 7 days. Started Feb 2025; status: terminated.
02
Drugs
Nezavist SDD
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06633562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06633562.